RFP
CHRS icon

Root Financial Partners’s Coherus Oncology CHRS Stock Holding History

Root Financial Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-199
Closed -$336 – 926
2026
Q1 		$336 Buy
+199
New +$353 ﹤0.01% 2993

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Root Financial Partners's CHRS Position: Q2 2026 in Review

Root Financial Partners sold out of Coherus Oncology (CHRS) in Q2 2026, closing a stake of 199 shares — an estimated $336 sold.

Root Financial Partners first reported a position in CHRS in Q1 2026 and held it in 1 quarter. The position peaked at $336 in Q1 2026. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Root Financial Partners reported no remaining Coherus Oncology position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 199 Coherus Oncology shares in Q2 2026, an estimated $336.
  • Root Financial Partners first reported a position in Coherus Oncology in Q1 2026 and held it in 1 quarter.
  • Root Financial Partners's Coherus Oncology position peaked at $336 in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.